Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy

NCT07603856 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT07603856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07603856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Recruiting
Start date
December 12, 2026
Completion date
June 25, 2030
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic lung cancer, non-small cell lung cancer